RxDoctor Payments Data

Henry Fosah, MD

Family Medicine · Abilene, TXNPI 1992935456

Payments from drug & device makers

$564in general payments, 2019–2025

Across 26 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$222
  • AbbVie$189
  • GSK$119
  • Sumitomo Pharma America, Inc.$19
  • Exact Sciences$16

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$222
AbbVie(2 entities)16$189
GSK5$119
Sumitomo Pharma America, Inc.1$19
Exact Sciences1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$564 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$149,059
Medicare patients
379
Services billed
1,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide206$238,183
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$91,093
FarxigaDapagliflozin Propanediol67$68,814
LinzessLinaclotide68$59,639
JanuviaSitagliptin Phosphate53$53,282
EliquisApixaban45$36,678
JardianceEmpagliflozin21$22,542
XareltoRivaroxaban16$16,218
TradjentaLinagliptin13$15,624
MyrbetriqMirabegron15$15,241
TrulicityDulaglutide15$13,984
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$13,605
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,004
SymbicortBudesonide/Formoterol Fumarate42$10,968
Tresiba Flextouch U-100Insulin Degludec20$10,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$222$238,183206 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$119$110,793141 claims
AbbVieLinzess$189$59,63968 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →